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Resident and ‘‘Inflammatory’’ Dendritic Cells in Human
Skin
Lisa C. Zaba1, James G. Krueger1 and Michelle A. Lowes1
Dendritic cells (DCs) are a heterogeneous group of
antigen-presenting leukocytes that are important in
activation of both the innate and adaptive arms of the
immune system. Although there are several different
DC populations in the body, DCs are globally defined
by their capacity for potent antigen presentation and
naive T-cell activation. In noninflamed human skin
during steady state, there are three main cutaneous
DC populations: epidermal Langerhans cells, dermal
myeloid DCs, and dermal plasmacytoid DCs. In
psoriasis, a model for cutaneous inflammation, there
is an additional population of myeloid dermal DCs—
‘‘inflammatory DCs’’—which appears to be critical for
disease pathogenesis.
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INTRODUCTION
The term ‘‘dendritic cell’’ (DC) was coined in 1973 when
DCs in the lymph node were discovered by Ralph Steinman
and Zanvil Cohn (Steinman and Cohn, 1973). These DCs
were identified as potent antigen-presenting cells in the
mixed leukocyte reaction. However, it took a number of
years for scientists to understand the significance and
potential roles of these cells, and now we know that they
are central in generating and regulating immune responses.
Retrospectively, it was appreciated that Langerhans cells
(LCs) described in the epidermis of the skin nearly 140 years
ago (Langerhans, 1868) were also DCs.
DCs are a heterogeneous population of cells in the
immune system, defined initially by their appearance, but
more specifically by their potent ability to present antigen to
T cells. Standardized characterization of human cutaneous
DC populations is complicated by pleiomorphic phenotype
and function during emigration from the skin for ex vivo
study, and by the great number of potential surface and
intracellular antigens that are present on these leukocytes. In
addition, there are differences between human and murine
DC networks. DC populations have been historically
classified either spatially (circulating blood DCs, draining
lymph node DCs, epidermal DCs, and dermal DCs), by their
presumed origin (myeloid DCs, plasmacytoid DCs (pDCs)),
by physiological or pathophysiological state (steady-state
DCs, inflammatory DCs), or by antigen expression (Langerin,
DEC-205 and so on). We review our current classification of
DC subsets contained within human skin during steady state
and inflammation (Figures 1 and 2). Our main message is that
there are three cutaneous DC populations in the steady
state—epidermal LCs, resident dermal myeloid DCs, and
pDCs—and during inflammation there appears to be an
additional population of myeloid dermal ‘‘inflammatory’’
DCs. Understanding these DCs may lead to new therapeutic
targets for augmenting or suppressing inflammation during
human disease (Steinman and Banchereau, 2007).
LANGERHANS CELLS
LCs reside in the suprabasal layers of the epidermis wedged
in between, and in close contact with, keratinocytes. The
stellate appearance of these cells led researchers to believe
that they were of neural origin until over 100 years later,
when their role in antigen presentation was elucidated
(Braathen and Thorsby, 1980). LCs were initially identified
by the electron-dense organelle, the Birbeck granule, which
has a unique tennis-racket appearance. The function of
Birbeck granules is still unclear, but likely includes receptor-
mediated endocytosis and transport of cellular materials into
the extracellular space (Mc Dermott et al., 2002). The first
monoclonal antibody that clearly identified LCs bound to
CD1a, a major histocompatibility complex I-like molecule
that presents microbial lipids to T cells (Thomas et al., 1984;
Barral and Brenner, 2007). More recently, the monoclonal
antibody to Langerin/CD207 has been used to specifically
recognize LCs (Figure 2). Langerin/CD207 is a membranous
C-type lectin discovered by Valladeau et al, (2000) that
recognizes mannosylated ligands found on the surface of a
wide range of pathogens, including viruses, bacteria, fungi,
and protozoa (Figdor et al., 2002). Following receptor-
mediated endocytosis, CD1a and Langerin/CD207 traffic to
the Birbeck granule where they may participate in antigen
processing (Sto¨ssel et al., 1990).
Elegant studies by Merad et al. (2002, 2004) have recently
shed light on the origin and trafficking of LCs during steady
state and inflammation It now seems clear that epidermal LCs
are continuously replaced from a resident precursor pool
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(perhaps by self-renewal) throughout life under steady-state
conditions (Merad et al., 2002). However following inflam-
mation, LCs are repopulated by blood precursors, most likely
monocytes (Ginhoux et al., 2006). In human psoriasis
vulgaris, there are variable reports of the number and
arrangement of LCs in the epidermis adjacent to noninflamed
epidermis. This may be due to different staining and counting
methods used for analysis, or nonequivalent patient popula-
tions. In our studies on stable plaque psoriasis, we have found
that LCs in lesional and nonlesional epidermis are of similar
number per linear surface, with a redistribution to the upper
layers of the thickened psoriatic epidermis, and express
comparable antigen markers (Krueger JS, unpublished data).
These observations are supported by studies showing that LC
migration in psoriasis is impaired, leading to retention of LCs
in psoriatic inflammation (Cumberbatch et al., 2006). Further
studies need to be performed to evaluate LCs during human
disease states using these new markers.
Interest in LCs has increased with three key observations.
First, in mice, there is a newly discovered population of
Langerinþ DCs in the dermis and skin-draining lymph nodes
(Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al.,
2007). These epidermal and dermal LC populations have
distinct phenotypic and mitotic capacities, and the dermal
Langerinþ LCs do not appear to be simply epidermal LCs en
route to the draining lymph node (Stoitzner et al., 2003,
2005; Douillard et al., 2005). Epidermal LCs are
LangerinþCCR6þCCR7þ /, radioresistant, slowly self-repli-
cating (Merad et al., 2002), and are highly responsive to
CCR6 agonist macrophage inflammatory protein-3a (CCL20)
(Larregina et al., 2001). In contrast, dermal LCs are
LangerinþCCR2þCCR7þ /, radiosensitive, rapidly self-
replicating, and are responsive to CCR2 agonist monocyte
Macrophages
CD163+
FXIIIA+
Plasmacytoid DCs
Inflammatory DCs
Resident dermal DCs
Langerhans cells
CD303/BDCA-2+
CD1c/BDCA-1–
CD1c/BDCA-1+
CD123+
CD11c–
CD11c+
CD11c+
CD1a+
CD207/Langerin+
HLA-DR+
HLA-DR+
HLA-DR+
HLA-DR+
TNF+
iNOS+
IL12/23p40+
IFN-α/β+
InflamedSteady state
Figure 1. Dendritic cell and macrophage populations in human skin during
steady state and inflammation. Noninflamed skin contains epidermal
Langerhans cells, CD1c/BDCA-1þ resident dermal DCs, plasmacytoid DCs,
and macrophages. In addition, inflamed skin contains a large population of
myeloid ‘‘inflammatory’’ DCs. Common markers used to identify these
leukocyte populations are indicated.
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Figure 2. Dendritic cell populations in nonlesional and lesional psoriatic
skin. H&E staining demonstrates characteristic features of psoriasis (right),
with epidermal acanthosis, elongation of rete ridges, parakeratosis (retention
of nuclei in stratum corneum), enlarged blood vessels, and marked leukocytic
dermal infiltrate. Immunohistochemistry of nonlesional and lesional psoriatic
skin for Langerhans cells (Langerin), resident dermal DCs (CD1c/BDCA-1þ ),
resident and inflammatory myeloid DCs (CD11c), and plasmacytoid DCs
(BDCA-2). (Insert) High power magnification of each cell type is
approximately 60-mm length. Bar¼ 100mm.
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chemoattractant protein-1 (CCL2) (Bursch et al., 2007;
Ginhoux et al., 2007; Poulin et al., 2007), although CCR6
expression and responsiveness to CCL20 have not yet been
investigated in these dermal Langerinþ CCR2þ cells.
LangerinþCD1aþ dermal LCs may also exist in human skin
(Angel et al., 2006), although we have not been able to
identify many dermal LCs in normal or psoriatic skin in situ
(unpublished data; Lowes et al., 2005b).
Second, there is much debate concerning the pathophy-
siologial role of LCs. Until recently it was assumed that
cutaneous antigens were locally processed by epidermal LCs,
which then migrate out of the skin into the draining lymph
node for efficient antigen presentation to T cells. During this
journey to the lymph node, the LCs change their surface
phenotype and ‘‘mature’’, simultaneously downregulating
antigen processing and acquiring improved ability for T-cell
co-stimulation (Larregina and Falo, 2005). Recent studies
have questioned the biological significance of this pathway
as antigen-specific T-cell activation remains intact in LC-
deficient murine models (Mommaas et al., 1994; Zhao et al.,
2003; Ritter et al., 2004; Bennett et al., 2005; Kaplan et al.,
2005; Kissenpfennig et al., 2005a). However, inconsistent
results were obtained in these studies that may be due to
many factors, such as the mode of LC depletion (constitutive
or induced), the site of challenge (epidermis versus epidermis
and dermis), the dose of antigen, and the timing of contact
hypersensitivity schedules. To date, no model claiming to
show the redundancy of LCs in the induction of immunity has
used a strictly epidermotropic pathogen, for example,
papillomavirus. Third, another group recently published a
novel role for these cells, describing how LCs expressing
ligands for cytotoxic T cells unexpectedly promoted murine
carcinogenesis (Strid et al., 2008).
These new observations suggest that there is steady-state
migration of LCs to skin-draining lymph nodes, perhaps to
induce and maintain tolerance to cutaneous antigens (Stein-
man and Nussenzweig, 2002). Thus a working hypothesis is
emerging whereby DCs that reside in the dermis may be
essential for the process of cutaneous immune activation,
whereas LCs may be more important in sustaining cutanous
immunological tolerance.
DERMAL DCs
The population of DCs that reside in the dermis of the skin are
known as dermal DCs, and these are considered analogous to
‘‘interstitial DCs’’ found in the connective tissue and stroma
of other organs (Lenz et al., 1993; Nestle et al., 1993;
Shortman and Naik, 2007). These important cells have
the capacity to take up cutaneous antigens, mature and
migrate to draining local lymph nodes, and present these
antigens to T and B cells (Dubois et al., 1998; Nestle et al.,
1998; Kissenpfennig et al., 2005b). This process may be
essential during skin infections, such as herpes simplex, as
blockade of dermal DC migration from skin to lymph node
may prevent effective cytotoxic T-cell activation (Allan et al.,
2006).
Because culture methods change the surface cellular
phenotype, the purest phenotypic classification of dermal
DCs is best performed in situ, followed by ex vivo functional
verification of antigen-presenting capacity. Unfortunately,
there is no single or specific marker for these cells, although
the integrin CD11c is probably the best tool we currently
have to identify them. For many years, antibodies to Factor
XIIIA clotting factor were used to identify a dermal population
of cells that have multiple dendritic processes protruding
from a stellate-shaped cell body, and were thus called
‘‘dermal dendrocytes’’ (Headington, 1986). In 1993,
Meunier et al. (1993) described a small population of HLA-
DRþCD11cþCD1cþFXIIIAþ cells from cultured normal
human dermis that had the capacity to stimulate T cells in
a mixed leukocyte reaction . In addition, Nestle et al. (1994)
showed that immunostimulatory dermal DC populations
were present from psoriatic skin. However, it has recently
been demonstrated that factor XIIIA is induced with culture
and is actually a macrophage marker, rather than a specific
DC marker (To¨ro¨csik et al., 2005; Zaba et al., 2007b). Thus,
more work needs to be performed to reevaluate the body of
literature classifying dermal antigen-presenting cells as
FXIIIAþ .
Resident dermal DCs
To understand dermal DCs and to develop working models to
study these cells, we and others have developed the concept
that there is a resident population of dermal DCs, as well as
an additional group of DCs that appear or develop during
inflammation (‘‘inflammatory’’ dermal DCs) (Shortman and
Naik, 2007). A proportion of resident murine steady-state
dermal DCs (CD11cþ ) appear to be able to proliferate in situ
to maintain the baseline population (Bogunovic et al., 2006).
The major resident population in normal dermis is identified
phenotypically with a single monoclonal antibody, CD1c,
which is also known as blood dendritic cell antigen (BDCA)-1
(Figure 2). Anti-BDCA antibodies-1 (CD1c), -2 (CD303), -3
(CD141), and -4 (CD304/neuropilin-1) recognize proteins
that were first used to identify circulating DCs (Dzionek et al.,
2000; MacDonald et al., 2002). In steady state, CD1cþ
(BDCA-1) DCs are relatively immature with modest T-cell
stimulatory ability, but their immunostimulatory capacity can
be greatly increased with DC maturing stimuli (Zaba et al.,
2007b). These CD1cþ (BDCA-1) DCs are also CD11cþHLA-
DRþCD45þCD14, are mostly DC-specific ICAM-3-
grabbing nonintegrin/CD209þ , and by flow cytometric
analysis are approximately 50% low level CD1aþ (unpub-
lished data). CD1cþCD14CD1aþ dermal DCs from normal
skin are also CCR7þ and are responsive to the lymph node
chemokine CCL19, suggesting that these cells can migrate to
draining lymph nodes for antigen presentation (Angel et al.,
2006). Before these experiments, it had been previously
shown that dermal DCs associating with T cells in normal
skin display an activated phenotype (Pope et al., 1995;
McLellan et al., 1999). It is possible that these immature
CD1cþ (BDCA-1) resident DCs are tolerogenic in steady
state, analogous to epidermal LCs.
CD1a has also been used to specifically identify immuno-
stimulatory dermal DCs in normal skin (Lenz et al., 1993;
Nestle et al., 1993; Angel et al., 2006, 2007) and in psoriasis
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(Nestle et al., 1994). In normal skin, dermal CD1aþ cells
appear to be CD1cþ (BDCA-1) in situ and also in single cell
suspensions, although CD1a stains dermal cells at lower
intensity compared to epidermal Langerhans cells (unpub-
lished data). This suggests that dermal CD1aþ cells may be a
subset of the resident myeloid DCs, but CD1cþ (BDCA-1þ )
may be a more useful marker of these cells as it co-localizes
with nearly all the CD11cþ cells. Second, there are reports of
an additional population of dermal antigen-presenting cells
identified by CD14þ (Morelli et al., 2005; Angel et al.,
2007). In our studies, there are few CD14þ cells in normal
skin in situ (unpublished data) and it is not yet clear if these
are indeed dermal residents. When the skin is cultured to
produce dermal single cell suspensions, it is possible that
there are contaminating monocytes. Future studies are
required to clarify the CD14þ dermal population and the
role of the CD1aþCD1cþ dermal DC subset.
Although most of these CD1cþ (BDCA-1) cells are
relatively immature, there is a small subgroup (B5%)
expressing mature DC markers (Zaba et al., 2007b). This
includes DC-lysosomal-associated membrane protein/
CD208, and endocytic receptor DEC-205/CD205 that is
present on immature DCs, but markedly upregulated on
maturation (Guo et al., 2000; Butler et al., 2007). These rare,
phenotypically mature cells often aggregate together in
dermal clusters, but their scarcity prevents detailed functional
analysis. Perhaps normal skin requires a small population of
mature DCs for fast antigen presentation to local T cells, or
for ongoing ‘‘micro’’ immune responses.
In normal skin, there is also a population of dermal DCs
identified by CD141 (BDCA-3). These CD141þ (BDCA-3)
cells constitute approximately 10% of all CD11cþ dermal
DCs and do not overlap with CD1cþ (BDCA-1) DCs (Zaba
et al., 2007b). Again, functional analysis has not been per-
formed on dermal CD141þ (BDCA-3) cells due to their low
frequency. However, it has been established that CD141þ
(BDCA-3) DCs in blood are nonoverlapping with blood
CD1cþ (BDCA-1) DCs and are the least immunostimulatory
myeloid blood DC population (MacDonald et al., 2002).
‘‘Inflammatory’’ dermal DCs
Psoriatic inflammation induces dramatic changes in dermal
DC populations, most obviously a 30-fold increase in
CD11cþ DCs in the dermis (approximately equal to T-cell
numbers) (Zaba et al., 2007a) (Figure 2). These DCs return to
normal or nonlesional levels with effective treatment (Lowes
et al., 2005b; Zaba et al., 2008). Characterization of these
cells during inflammation is not yet complete, but our
preliminary studies suggest that they are not CD1cþ
(BDCA-1), that is, these ‘‘inflammatory’’ myeloid dermal
DCs are CD11cþCD1c. This indicates that they may be
derived from circulating DC precursors migrating into the
skin due to inflammatory and chemotactic signals. Potential
precursors include circulating hematopoietic precursor cells
(Svensson and Kaye, 2006; Massberg et al., 2007), circulating
‘‘pre-DCs’’ (CD11cþ HLA-DRhi, CD16þ ) (Randolph et al.,
2002; Tacke and Randolph, 2006; Piccioli et al., 2007),
monocytes (Serbina et al., 2003), or resident DCs.
In psoriasis, we have been able to determine that dermal
DCs produce mediators, such as tumor necrosis factor and
intracellular nitric oxide synthase, which have been termed
tumor necrosis factor and inducible nitric oxide synthase-
producing DCs (Tip-DCs) (Lowes et al., 2005a). It is likely
that these Tip-DCs are contained within the CD11cþCD1c
population of ‘‘inflammatory’’ myeloid DCs in psoriasis
lesions (Zaba et al., 2008). Tip-DCs were first described in
a murine model of Listeria monocytogenes infection (Serbina
et al., 2003) and have also been found in murine Escherichia
coli bladder infection (Engel et al., 2006). In humans, the
location and functions of Tip-DCs are emerging: they are
present in the lamina propria of the gut where they may be
important for immunoglobulin A production (Tezuka et al.,
2007), and they appear to be induced by topical imiquimod
treatment of basal cell carcinoma (Stary et al., 2007), so they
may participate in tumor rejection. Pathogenicity of these
Tip-DCs in psoriasis is suggested by the rapid downmodula-
tion of Tip-DC products tumor necrosis factor, inducible
nitric oxide synthase, IL-20, and IL-23 during treatment with
effective therapies (Zaba et al., 2007a; Haider et al., 2008).
Tip-DCs can also stimulate the differentiation and activation
of Th17 T cells, which are a new set of T cells associated with
autoimmune inflammation in many disease models (Zaba
et al., 2008). The potential role of these DCs as sources of
inflammatory mediators is in contrast to the classic role of
DCs as antigen-presenting cells, and warrants further atten-
tion. Because these DCs may actually be the key target of a
variety of anti-inflammatory therapies, and may be broadly
involved in ‘‘autoimmune’’ inflammation of many different
human diseases, we need to better understand the develop-
ment and activation of these cells.
In another common skin disease, atopic dermatitis, a
population of inflammatory DCs have also been described.
These cells were initially termed inflammatory dendritic
epidermal cells based on flow cytometric analysis of cells
from epidermal cell suspensions (Wollenberg et al., 1996,
2002; Novak and Bieber, 2005). Inflammatory dendritic
epidermal cells were defined by the following: HLA-
DRþLinCD11cþCD1aþ and these DCs co-express
CD206/macrophage mannose receptor, CD36, FceRI,
immunoglobulin E, CD1b/c, CD11b, as well as DC-specific
ICAM-3-grabbing nonintegrin/CD209 (Guttman-Yassky et al.,
2007). There is now appreciation that these DCs are also
located in the dermis and appear to produce a different array
of cytokines and chemokines (Th2 chemokines CCL17 and
CCL18) than do psoriatic inflammatory DCs, and do not have
an inducible nitric oxide synthase signature (Guttman-Yassky
et al., 2007). Thus the cutaneous inflammatory millieu may
drive the differentiation of different types of inflammatory
DCs that contribute specifically to the disease process and
even clinical phenotype.
PLASMACYTOID DCs
PDCs are an additional unique population of resident
cutaneous DCs initially described by their morphology,
which is similar to a plasma cell (Corcoran et al., 2003).
There are considerable phenotypic and functional differences
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of PDCs in humans and mice, which may contribute to the
confusion in the literature as to their precise role in immune
responses (Valladeau and Saeland, 2005). PDCs share many
characteristics with B cells, including dependence on a B-cell
transcription factor (SPI-B), and immunoglobulin gene
rearrangements. It now appears that both PDCs and myeloid
DCs may actually arise from a bone marrow-derived
common DC precursor (Naik et al., 2007; Onai et al.,
2007). Although both myeloid and pDCs express high levels
of HLA-DR and have the capacity to present antigen, pDCs
are characterized by their ability to produce large amounts of
type 1 interferon (IFN) (IFN-a, b, o) during viral infection—
10,000 fold more IFN than any other cell type (Kadowaki
et al., 2000; Ito et al., 2004). This potent IFN production is
induced by viral RNA and DNA containing repeated
unmethylated CG nucleotide (CpG) binding to Toll-like
receptor 7 and Toll-like receptor 9 endosomal receptors,
and the CpG class determines the level of IFN produced
(Rothenfusser et al., 2002). IFN-a, the most studied of the
Type I IFNs, modulates development and maturation of many
immune cells, including T cells and myeloid DCs, by binding
to abundantly expressed IFN receptor (Theofilopoulos et al.,
2005). In addition, different stimulation conditions (for
example, influenza virus and CpG) may induce distinct
activation states in pDC (Iparraguirre et al., 2008). The
pleiotropic effects of pDC activation are complicated and not
fully understood.
Monoclonal antibodies for pDC identification are well
developed and include CD123/IL-3R, BDCA-2, and BDCA-4.
BDCA-2 is the only marker that is exclusive to pDCs, as
myeloid DCs can express low levels of CD123 and BDCA-4
(Liu, 2005). Thus, a common phenotypic definition of blood
and tissue pDCs is HLA-DRþCD11cCD123hiBDCA-2þ .
Research on the function of human pDCs during steady state
and disease is limited by low frequency and transitory
expression of IFNa (Nestle and Gilliet, 2005).
In studies of normal skin, there are a small number of
pDCs (Ebner et al., 2004; Zaba et al., 2007b), and there does
not appear to be any marked increase in the frequency of
these cells in chronic large plaque psoriasis (Guttman-Yassky
et al., 2007), although others have found an increase of these
cells in psoriasis (Nestle et al., 2005). However, two recent
observations support a role for pDCs during the initiation
phase of psoriasis. First, in xenotransplant experiments of
nonlesional skin from patients with psoriasis grafted onto
immunosuppressed mice, the stress of transplantation is
sufficient for psoriasis to develop spontaneously in the graft
(Nestle and Nickoloff, 2005). Blockade of IFN-a prevented
development of psoriasis, implicating pDCs as they are the
primary source of IFN-a in the skin. Second, keratinocyte
peptide LL37 (also known as cathelicidin or cathelicidin
antimicrobial peptide (cyclic AMP)) binds to self-DNA and
Toll-like receptor 9 in pDCs, and induces IFN-a (Lande et al.,
2007). Expression of this antimicrobial peptide is increased
during inflammation such as psoriasis, and downstream
effects of this increased IFN-a production may be activation
of myeloid DCs and initiation of psoriasis (Nestle and Gilliet,
2005). Patients with psoriasis may have pDCs that are
particularly sensitive to LL37 and respond in an exaggerated
manner with increased IFN-a induction, thus setting in
motion psoriatic inflammation.
SUMMARY
DC heterogeneity and complexity has made them difficult to
understand, but we are currently developing better tools and
models to study these cells. DCs are central orchestrators of
innate and cellular immune responses, either by secretion of
bioactive cytokines or inflammatory mediators that modulate
stromal and local cutaneous immunocytes, or by their ability
to directly activate T cells. Currently, we do not know the
relative contribution or temporal involvement of DC subsets,
T cells, and keratinocytes in initiating and maintaining skin
inflammation. The data summarized here indicate that DCs
are important in cutaneous homeostasis and are likely central
to pathogenic processes in the skin. This information from the
skin may also be applicable to other organs, systems, and
diseases. Further studies on cutaneous DCs are essential if we
are to tap into the enormous therapeutic potential of these
fascinating cells.
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